Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trialYehuda Carmeli, Surbhi Malhotra‐Kumar, George Singer et al.|The Lancet Infectious Diseases|2024Cited by 98
2893 A. Efficacy and Safety of Aztreonam-Avibactam for the Treatment of Serious Infections Due to Gram-Negative Bacteria, Including Metallo-β-Lactamase-Producing Pathogens: Phase 3 REVISIT StudyYehuda Carmeli, Joseph W. Chow, Francis F. Arhin et al.|Open Forum Infectious Diseases|2023Cited by 25